NCT01350115View on ClinicalTrials.gov

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Basal Cell CarcinomaGorlin SyndromeNevoid Basal Cell Carcinoma Syndrome
Interventions
DRUG

LDE225

supplied as 100 mg capsules

DRUG

Placebo

supplied in capsules

Trial Locations (6)

3000

Novartis Investigative Site, Leuven

24105

Novartis Investigative Site, Kiel

A-1090

Novartis Investigative Site, Vienna

L3P 1A8

Novartis Investigative Site, Markham

N2J 1C4

Novartis Investigative Site, Waterloo

H2K 4L5

Novartis Investigative Site, Montreal

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY